GWM
SUPN icon

Geneos Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Geneos Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-108
Closed -$3.4K – 3107
2025
Q2 		$3.4K Sell
108
-50
-32% -$1.6K ﹤0.01% 2677
2025
Q1 		$5.17K Buy
158
+129
+445% +$4.57K ﹤0.01% 2744
2024
Q4 		$1.05K Buy
29
+9
+45% +$317 ﹤0.01% 2757
2024
Q3 		$624 Buy
+20
New +$624 ﹤0.01% 2521
2022
Q3 		– Sell
-170
Closed -$4K – 2529
2022
Q2 		$4K Sell
170
-5
-3% -$143 ﹤0.01% 2278
2022
Q1 		$5K Buy
175
+5
+3% +$153 ﹤0.01% 2359
2021
Q4 		$4K Hold
170
– – ﹤0.01% 2486
2021
Q3 		$4K Hold
170
– – ﹤0.01% 2532
2021
Q2 		$5K Hold
170
– – ﹤0.01% 2462
2021
Q1 		$5K Hold
170
– – ﹤0.01% 2674
2020
Q4 		$4K Hold
170
– – ﹤0.01% 2562
2020
Q3 		$3K Hold
170
– – ﹤0.01% 2340
2020
Q2 		$3K Hold
170
– – ﹤0.01% 2302
2020
Q1 		$2K Hold
170
– – ﹤0.01% 2297
2019
Q4 		$4K Hold
170
– – ﹤0.01% 2260
2019
Q3 		$4K Hold
170
– – ﹤0.01% 2179
2019
Q2 		$5K Hold
170
– – ﹤0.01% 2129
2019
Q1 		$5K Hold
170
– – ﹤0.01% 2059
2018
Q4 		$5K Hold
170
– – ﹤0.01% 2004
2018
Q3 		$8K Hold
170
– – ﹤0.01% 1934
2018
Q2 		$10K Hold
170
– – ﹤0.01% 1734
2018
Q1 		$7K Sell
170
-117
-41% -$4.88K ﹤0.01% 1782
2017
Q4 		$11K Hold
287
– – ﹤0.01% 1616
2017
Q3 		$11K Sell
287
-1,644
-85% -$71.1K ﹤0.01% 1552
2017
Q2 		$83K Buy
1,931
+969
+101% +$34.5K 0.01% 740
2017
Q1 		$30K Buy
962
+635
+194% +$17K ﹤0.01% 1091
2016
Q4 		$8K Buy
327
+40
+14% +$894 ﹤0.01% 1514
2016
Q3 		$7K Buy
287
+117
+69% +$2.65K ﹤0.01% 1494
2016
Q2 		$3K Hold
170
– – ﹤0.01% 1633
2016
Q1 		$2K Buy
+170
New +$2.22K ﹤0.01% 1689

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Geneos Wealth Management's SUPN Position: Q3 2025 in Review

Geneos Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 108 shares — an estimated $3.4K sold.

Geneos Wealth Management first reported a position in SUPN in Q1 2016 and held it in 30 quarters. The position peaked at $83K in Q2 2017. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Geneos Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 108 Supernus Pharmaceuticals shares in Q3 2025, an estimated $3.4K.
  • Geneos Wealth Management first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 30 quarters.
  • Geneos Wealth Management's Supernus Pharmaceuticals position peaked at $83K in Q2 2017.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.